关键词: 他罗利姆;小肠/移植;药代动力学

    摘 要:目的 了解普乐可复(FK506)在亲体小肠移植患者体内药代动力学的规律，为临床小肠移植患者制定个体化用药方案. 方法 在患者FK506血药浓度达稳态条件下，于一个给药周期(τ)内间隔采集患者全血11次，以微粒子酶免分析法(MEIA)测定FK506全血浓度，以3P97药动学程序拟合求算FK506在患者体内的药动学参数，以该患者个体的药动学参数为依据，为其实施个体化用药. 结果 在患者po FK506(5mg·12h-1 )稳态时，FK506在该患者体内的处置为一室开放模型，其主要的药动学参数:达峰时间Tmax 、最大全血浓度ρ max 、消除相半衰期t1/2 ke、曲线下面积AUC分别为1.4h，25.1μg·L-1 ，8.8h和355.7μg·h-1 ·L-1 ，FK506全血浓度波动差值为13.7μg·L-1 . 结论 为降低FK506全血浓度波动范围，采用8h1次po FK506更为适宜，同时应加强FK506血药浓度监测，确保用药安全和有效.

    Individual medication of FK506in the recipient of the first case of living┐related small bowel trans┐plantation in China

    WEN Ai-Dong WANG Wei-Zhong SONG Wei-Liang ZHAO Lei WU Guo-Sheng ZHAO Jing-Xia

    1 Department of Pharmacy，

    2 Department of Gas-trointestinal Surgery，Xijing Hospital，Fourth Mili-tary Medical University，Xi'an710033，China

    Keywords:tacrolimus;intestine，small/transplantation;pharmacokinetics

    Abstract:AIM To investigate the clinical pharmacokinetics of FK506in the recipient of living-related small bowel trans-plantation and to provide gist for clinical individual dosage.METHODS When level of FK506had achieved steady state ......